Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206408 | 0.88 | NR1H3 (0.45) | NR1H3CYSLTR2CYSLTR1 | |
| SCHEMBL26205853 | 0.87 | HDAC1 (0.42) | MTNR1AMTNR1BSIRT2 | |
| SCHEMBL26206114 | 0.86 | HDAC1 (0.46) | MTNR1AMTNR1B | |
| SCHEMBL26206109 | 0.85 | HDAC1 (0.48) | MTNR1AMTNR1B | |
| SCHEMBL3980690 | 0.83 | SLC7A5 (0.47) | SLC7A5MTNR1AMTNR1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL3981146 | 0.83 | SLC7A5 (0.47) | SLC7A5MTNR1AMTNR1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL3980691 | 0.83 | SLC7A5 (0.47) | SLC7A5MTNR1AMTNR1BSMN1; SMN2ALDH1A1 | |
| SCHEMBL22526755 | 0.80 | PPARA (0.42) | MTNR1AMTNR1BCYSLTR2CYSLTR1 | |
| SCHEMBL26206366 | 0.80 | PPARA (0.47) | SMN1; SMN2CYSLTR2CYSLTR1 | |
| SCHEMBL22526462 | 0.80 | CACNA1B (0.40) | SLC7A5MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | SLC7A5 4151/4885MTNR1A 1433/4885MTNR1B 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.